Journey Medical Corporation
As of Oct 22, 2026, Journey Medical is in Stage 3, the topping phase, now in week 3 (since Oct 7, 2026). It closed at $5.09, 45.0% below its 52-week high and below its 200-day average, which is falling.
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is DERM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DERM among Drug Manufacturers - Specialty & Generic46th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …46 | DERM | Stage 3 · wk 3 | 33 | −21.7% |
Journey Medical: quick answers
What stage is Journey Medical in?
As of Oct 22, 2026, Journey Medical (DERM) is in Stage 3, the topping phase. It entered Stage 3 on Oct 7, 2026 and is in week 3. What the four stages mean
Is Journey Medical in an uptrend?
Its uptrend has stalled. Journey Medical is in Stage 3, the topping phase that follows an advance. It trades 24.2% below its 200-day average, which is falling.
How far is Journey Medical from its 52-week high?
Journey Medical closed at $5.09 on Oct 22, 2026, 45.0% below its 52-week high of $9.26. Its 52-week low is $4.39.
How has Journey Medical performed over the past year?
As of Oct 22, 2026, Journey Medical is down 30.7% over the past year and down 31.7% so far in 2026.
Which sector and industry is Journey Medical in?
Journey Medical is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.